Chapter 3 — Human Reproduction

Fig 1 — Educational Diagram: Introduction to Human Reproduction

Introduction to Human Reproduction

Human reproduction is the biological process by which new human individuals are produced. It ensures continuity of the species and involves specialized organs, cells (gametes), hormones and a sequence of events from gametogenesis to birth and early postnatal care.

Major components

• Reproductive organs: Male (testes, epididymis, vas deferens, seminal vesicles, prostate, penis) and female (ovaries, fallopian tubes, uterus, cervix, vagina, mammary glands).
• Gametes: Sperm (male gamete) and ovum (female gamete).
• Hormonal control: Hypothalamus-pituitary-gonadal axis regulates reproduction via GnRH, FSH, LH, estrogen, progesterone, inhibin and human chorionic gonadotropin (hCG) in pregnancy.

Key processes

• Gametogenesis: Spermatogenesis (continuous production of sperm in testes after puberty) and oogenesis (formation of oocytes, mostly prenatal; primary oocytes arrested until puberty; one dominant follicle usually matures per cycle).
• Menstrual cycle: A cyclical sequence in sexually mature females (average ~28 days) with ovarian phases (follicular, ovulation, luteal) and matching uterine changes (menstrual, proliferative, secretory) governed by changing hormone levels.
• Fertilization: Fusion of sperm and ovum usually in ampullary region of fallopian tube, forming a diploid zygote which undergoes cleavage and forms a blastocyst.
• Implantation and pregnancy: Blastocyst implants in uterine endometrium; placenta forms to support embryo/fetus; pregnancy lasts ~40 weeks from last menstrual period (LMP).
• Parturition and lactation: Childbirth is initiated by hormonal changes (e.g., oxytocin) and mechanical factors; mammary glands produce milk under prolactin and oxytocin influence for neonatal nutrition.

Regulation and feedback

Negative and positive feedback loops maintain balance: low sex steroid levels stimulate GnRH -> FSH/LH; rising estrogen/progesterone inhibit FSH/LH. A mid-cycle estrogen peak triggers LH surge causing ovulation.

Reproductive health and applications

• Family planning: contraceptive methods (barrier, hormonal, intrauterine devices) prevent unwanted pregnancy.
• Assisted reproductive technologies (ART): in vitro fertilization (IVF), intrauterine insemination (IUI) help treat infertility.
• Sexually transmitted infections (STIs) affect reproductive health; safe-sex practices and timely treatment are important.

Summary

Introduction to human reproduction covers anatomy, gamete formation, hormonal control, the menstrual cycle, fertilization, embryonic development, pregnancy and childbirth, and societal/medical aspects such as contraception and ART. Understanding these basics links physiology to health, family planning and clinical interventions.

Fig 2 — Educational Diagram: Male Reproductive System: Structure

Overview: The male reproductive system is specialized to produce, maintain and transport sperm and protective fluid (semen), and to discharge sperm within the female reproductive tract. Major components are the testes (primary gonads), ducts for sperm transport, accessory glands that form semen, and external genitalia.

External structures:

• Scrotum – a cutaneous pouch that holds the testes outside the abdominal cavity; provides an optimal lower temperature for spermatogenesis (~2–4°C below body temperature).
• Penis – organ for copulation and passage of urine; contains erectile tissues (corpora cavernosa and corpus spongiosum) and the urethra.

Testes (structure & histology):

• Each testis is enclosed by tunica vaginalis (outer serous layer) and tunica albuginea (fibrous capsule). The tunica albuginea sends septa that divide the testis into 200–300 lobules.
• Each lobule contains 1–4 seminiferous tubules, the site of sperm production. Seminiferous tubules converge into the rete testis and efferent ductules that lead to the epididymis.
• Sertoli cells (within seminiferous tubules) provide nutritional and structural support to developing germ cells, form the blood–testis barrier, and secrete inhibin and androgen-binding protein (ABP).
• Interstitial (Leydig) cells located between tubules produce testosterone under LH stimulation.

Spermatogenesis (brief):

• Sequence: spermatogonia (stem cells) → primary spermatocytes (meiosis I) → secondary spermatocytes (meiosis II) → spermatids → spermatozoa (spermiogenesis).
• Duration: ~64 days for humans (continuous process). Sertoli cells support differentiation and release mature sperm into the lumen.

Male duct system:

• Epididymis (head, body, tail) — site for sperm maturation and storage; tail stores mature sperm until ejaculation.
• Vas (ductus) deferens — thick-walled muscular tube that transports sperm from epididymis to ejaculatory duct during ejaculation.
• Ejaculatory ducts — formed by union of vas deferens and seminal vesicle ducts; open into prostatic urethra.

Accessory glands:

• Seminal vesicles — produce an alkaline, fructose-rich fluid (~60% of semen) that supplies energy for sperm and neutralizes vaginal acidity.
• Prostate gland — secretes slightly acidic, milky fluid containing enzymes and zinc that helps activate sperm; forms ~25–30% of semen.
• Bulbourethral (Cowper's) glands — secrete a small amount of mucus that lubricates urethra and neutralizes traces of acidic urine.

Seminiferous output & semen:

• Normal semen volume: ~1.5–5 mL per ejaculate; pH ~7.2–7.8 (slightly alkaline).
• Normal sperm concentration (WHO reference): ≥15 million sperm/mL (values are population-reference thresholds).
• Sperm structure: head (acrosome with enzymes for egg penetration), midpiece (mitochondria for ATP), tail/flagellum (motility).

Blood supply & spermatic cord:

• Spermatic cord contains the vas deferens, testicular artery, pampiniform plexus (venous network important for countercurrent heat exchange), lymphatics, and nerves.

Endocrine control (structure–function link):

• Hypothalamus secretes GnRH → pituitary releases FSH and LH. FSH acts on Sertoli cells to support spermatogenesis; LH stimulates Leydig cells to produce testosterone, which promotes development and maintenance of male reproductive structures and spermatogenesis. Inhibin from Sertoli cells provides negative feedback on FSH.

Clinical/functional notes:

• Vasectomy: ligation/cutting of both vas deferens to prevent sperm reaching ejaculate; sperm production continues but sperm are absorbed in epididymis/testis.
• Varicocele: dilation of pampiniform plexus raises testis temperature and may reduce sperm quality.
• Orchitis, torsion, testicular cancer are important conditions affecting structure and function.

Fig 3 — Educational Diagram: Male Reproductive System: Function

Overview

The male reproductive system produces, matures and delivers male gametes (sperm) and synthesises male sex hormone (testosterone). It consists of testes, ducts (epididymis, vas deferens, ejaculatory duct, urethra), accessory glands (seminal vesicles, prostate, bulbourethral glands) and external genitalia (penis, scrotum). Functions are coordinated locally in the testes and systemically by the hypothalamo-pituitary-gonadal axis.

1. Sperm production (spermatogenesis)

• Occurs in seminiferous tubules of testes. Germ cells develop through mitosis (spermatogonia), meiosis (primary → secondary spermatocytes → spermatids) and spermiogenesis (morphological maturation into spermatozoa).
• Time required: approximately 64 days in humans (range ~42–76 days depending on source).
• Sertoli cells provide physical support, nutrition and form the blood–testis barrier; they secrete inhibin to regulate FSH.

2. Hormonal control

• Hypothalamus secretes GnRH → anterior pituitary secretes FSH and LH.
• FSH acts on Sertoli cells to stimulate spermatogenesis and production of androgen-binding protein (ABP).
• LH acts on Leydig cells to stimulate testosterone synthesis. Testosterone supports spermatogenesis and external male characteristics.
• Negative feedback: testosterone inhibits GnRH and LH; inhibin inhibits FSH.

3. Sperm maturation, storage and transport

• Immature sperm leave seminiferous tubules to the epididymis where they complete maturation (gain motility and fertilising ability) and are stored.
• During ejaculation, sperm travel via vas deferens → ejaculatory ducts → urethra.

4. Accessory gland secretions

• Seminal vesicles: supply fructose (energy), prostaglandins and alkaline fluid (about 60% of ejaculate).
• Prostate gland: adds slightly alkaline, milky fluid that enhances sperm motility and neutralises vaginal acidity.
• Bulbourethral glands: secrete lubricating pre-ejaculate that neutralises residual acidity in urethra.

5. Erectile mechanism and ejaculation

• Erection: parasympathetic stimulation causes vasodilation of penile arterioles and engorgement of corpora cavernosa; venous outflow is compressed.
• Ejaculation: sympathetic and somatic reflexes force seminal fluid through urethra; internal urethral sphincter closes to prevent retrograde ejaculation.

6. Temperature regulation

• Optimal spermatogenesis requires scrotal temperature about 2–3°C below core body temperature. Regulation achieved by the pampiniform plexus (countercurrent heat exchange), cremaster and dartos muscles, and scrotal position.

Normal values commonly used in clinics

• Semen volume: ~2–5 ml per ejaculate.
• Sperm concentration: WHO lower reference limit >= 15 million/ml.
• Total sperm count per ejaculate: commonly >= 39 million.
• Progressive motility: >= 32–40% (varies by guideline).

Clinical and physiological significance

• Disorders: oligospermia (low count), asthenozoospermia (reduced motility), azoospermia (no sperm), hormonal defects (hypogonadism), varicocele (impaired thermoregulation), obstructive lesions, infections, genetic defects.
• Contraception examples: vasectomy blocks vas deferens; hormonal research aims at suppressing spermatogenesis via GnRH/FSH/LH manipulation.

Fig 4 — Educational Diagram: Female Reproductive System: Structure

Overview

The female reproductive system consists of primary gonads (ovaries) and accessory reproductive organs (oviducts/fallopian tubes, uterus, cervix, vagina), external genitalia (vulva) and accessory structures (mammary glands). Its structure is specialised to produce ova, receive sperm, allow fertilisation, support embryo/fetus and enable childbirth.

1. Ovaries

• Location & size: Paired, almond-shaped organs in the pelvic cavity lateral to the uterus.
• Surface & coverings: Germinal epithelium (surface epithelium) over tunica albuginea.
• Internal zones: Cortex (contains ovarian follicles at various stages) and medulla (blood vessels, nerves).
• Follicles: Primordial → Primary → Secondary → Tertiary (Graafian). Each follicle contains an oocyte surrounded by granulosa cells and theca cells. After ovulation, the remnants form the corpus luteum, then corpus albicans.
• Supporting structures: Ovarian ligament (to uterus), suspensory ligament/infundibulopelvic ligament (contains ovarian vessels), mesovarium (part of broad ligament).
• Blood supply & nerve: Ovarian artery (from abdominal aorta) and ovarian veins; rich innervation.

2. Fallopian Tubes (Oviducts)

• Parts: Infundibulum with fimbriae (captures ovum), ampulla (widest, common site of fertilisation), isthmus (narrow), intramural/uterine part.
• Structure: Mucosa with ciliated columnar epithelium and secretory cells (movements and nourishment of ovum/embryo), muscular layer for peristalsis, serosa.
• Clinical note: Most ectopic pregnancies implant in the ampulla due to abnormal transport.

3. Uterus

• Shape & regions: Pear-shaped organ — fundus, body, isthmus and cervix.
• Wall layers: Perimetrium (serosa), myometrium (thick smooth muscle responsible for contractions), endometrium (mucosa).
• Endometrium: Two layers — stratum basalis (regenerative) and stratum functionalis (sheds during menstruation). Endometrial thickness changes with cycle and prepares for implantation.
• Cervix: Narrow lower part with cervical canal, internal and external os; secretes mucus that changes in consistency with cycle.

4. Vagina

• Structure: Muscular, fibromuscular tube with rugae; lined by non-keratinised stratified squamous epithelium that provides resistance to friction.
• Physiology related: Acidic pH maintained by lactobacilli, provides barrier to pathogens and sperm environment.
• Hymen: A membranous fold of variable form at vaginal entrance.

5. External Genitalia (Vulva) & Mammary Glands

• Vulva: Mons pubis, labia majora/minora, clitoris (erectile tissue with sensory function), vestibule containing urethral and vaginal openings, Bartholin glands (lubrication).
• Mammary glands: Modified sweat glands composed of lobes and lobules with alveoli that produce milk; connected by lactiferous ducts to the nipple; supported by connective tissue and areola.

Microscopic features important for structure-function

• Ovarian follicle: oocyte + granulosa cells (FSH-responsive) + theca cells (androgen production) → steroidogenesis hub.
• Fallopian tube epithelium: cilia beat toward uterus to move ovum; secretions nourish the ovum/embryo.
• Endometrium: richly vascularised and glandular; the functionalis responds to ovarian steroids (estrogen/progesterone).

Clinical & functional correlations: Knowledge of structure explains procedures and conditions—IVF egg retrieval targets ovarian follicles; tubal ligation interrupts oviduct continuity; IUDs act within uterus; ectopic pregnancy occurs when embryo implants in tubal mucosa; menopause results from depletion of ovarian follicles.

Fig 5 — Educational Diagram: Female Reproductive System: Function

Overview
The female reproductive system produces gametes (ova), supports fertilisation, enables implantation and development of the embryo/fetus, and provides hormonal regulation of the reproductive cycle and pregnancy.

Main organs and their functions

• Ovaries – Produce ova by oogenesis and secrete steroid hormones: oestrogen (mainly estradiol) and progesterone. They contain follicles at various stages; one follicle typically becomes dominant each cycle.
• Fallopian tubes (uterine tubes) – Site of fertilisation (usually in the ampulla). Cilia and peristalsis move the ovum/zygote toward the uterus.
• Uterus – Receives the blastocyst and provides a site for implantation and embryonic/fetal development. Its endometrium undergoes cyclic changes (thickening, secretion) to support pregnancy.
• Cervix – Lower uterine opening; produces mucus that changes consistency during the cycle affecting sperm passage; acts as barrier during pregnancy.
• Vagina – Copulatory organ; birth canal; receives sperm and provides acidic environment affecting microbes.
• Accessory structures – Mammary glands (lactation under prolactin/oxytocin control), ligaments and blood supply supporting reproductive organs.

Ovarian and uterine cycles
The ovarian cycle has three phases: follicular phase (development of follicles & rising oestrogen), ovulation (release of ovum triggered by LH surge), and luteal phase (corpus luteum formation and progesterone secretion). The uterine (menstrual) cycle has three corresponding phases: menstrual (shed endometrium), proliferative (oestrogen-driven repair and thickening), and secretory (progesterone-driven secretion and receptivity for implantation).

Endocrine regulation

• Hypothalamus secretes GnRH in pulses → stimulates anterior pituitary.
• Pituitary secretes FSH (follicle development) and LH (ovulation, corpus luteum maintenance).
• Ovary produces oestrogen (negative feedback on FSH/LH during most of follicular phase; positive feedback just before ovulation causing LH surge) and progesterone (negative feedback on GnRH/FSH/LH during luteal phase).

Fertilisation, implantation and pregnancy maintenance
Fertilisation typically occurs in the ampulla of the fallopian tube; the zygote divides and becomes a blastocyst that implants into the endometrium about 6–9 days after ovulation. The implanted embryo releases hCG, which rescues the corpus luteum so it continues producing progesterone until the placenta takes over hormone production (around 8–12 weeks). Progesterone and oestrogen maintain the uterine lining and prevent new cycles.

Other functional points

• Fertilisation window – Sperm viable ~up to 5 days; ovum viable ~24 hours; therefore the fertile window is ~5 days before ovulation to 1 day after.
• Lactational amenorrhoea – Frequent breastfeeding raises prolactin and suppresses GnRH/LH/FSH, often delaying return of ovulation.
• Menopause – Permanent cessation of ovarian cycles due to depletion of follicles; reduced oestrogen/progesterone, increased FSH/LH.

Clinical/physiological relevance
Problems in any step (anovulation in PCOS, blocked tubes, luteal phase defects, endometrial receptivity issues) can cause infertility. Contraceptives (combined oral pills, IUDs, implants) act by altering hormones or preventing fertilisation/implantation.

Fig 6 — Educational Diagram: Gametogenesis: Comparative Details

Overview: Gametogenesis is the process by which haploid gametes (sperm and egg) are produced from diploid germ cells by meiosis and cellular differentiation. In humans it occurs as spermatogenesis (male) and oogenesis (female). Both ensure reduction of chromosome number, genetic variation by recombination and independent assortment, and specialization of gametes.

Comparison — key points

• Site: Spermatogenesis in seminiferous tubules of testes (inside Sertoli cell environment). Oogenesis in ovarian follicles (within ovaries).
• Onset and duration: Spermatogenesis begins at puberty and continues throughout life (continuous). Oogenesis begins during fetal development (primordial follicles formed) with long arrests; completed only on fertilization for each oocyte — finite supply leading to menopause.
• Stem cells: Spermatogonia (type A) are the stem cells that divide throughout life. Oogonia are formed during fetal life; most differentiate to primary oocytes and no new oogonia appear after birth.
• Meiotic arrests: In females, primary oocytes arrest in prophase I (diplotene) from fetal life until puberty; the secondary oocyte arrests in metaphase II and completes meiosis II only after fertilization. In males there is no long meiotic arrest; meiotic divisions proceed continuously in adults.
• Number of functional gametes per primary cell: From one primary spermatocyte → 4 functional sperm. From one primary oocyte → typically 1 functional ovum + polar bodies (usually 2) — so one functional egg per primary oocyte.
• Size and cytoplasm: Sperm are small, motile, with minimal cytoplasm and condensed nucleus. Ovum is large, non-motile, rich in cytoplasm (yolk, organelles, mRNA) to support early embryogenesis. Cytoplasmic division is unequal in oogenesis producing polar bodies; spermatogenesis gives equal cytokinesis.
• Motility: Sperm are motile (flagellum). Ovum is non-motile; transport in female tract is by ciliary and muscular movements.
• Duration of process: Spermatogenesis takes ~64–74 days in humans from spermatogonial mitosis to mature sperm release. Oocyte maturation timeline is years to decades (primary oocyte arrested until stimulated to complete meiosis I monthly after puberty).
• Hormonal control: Both are regulated by hypothalamo–pituitary–gonadal axis. In males, FSH acts on Sertoli cells (support spermatogenesis) and LH acts on Leydig cells (testosterone production). In females, FSH stimulates follicle growth and estrogen secretion; LH surge triggers ovulation and corpus luteum formation.
• Genetic outcome: Both processes produce haploid gametes with recombined chromosomes; fertilization restores diploidy (2n).

Stages — brief

• Spermatogenesis: Spermatogonium (2n) → mitotic divisions → primary spermatocyte (2n) → meiosis I → 2 secondary spermatocytes (n, chromatids present) → meiosis II → 4 spermatids (n) → spermiogenesis (differentiation) → 4 spermatozoa.
• Oogenesis: Oogonium (2n, fetal) → mitosis → primary oocyte (2n) arrested in prophase I until puberty → meiosis I (just before ovulation) → secondary oocyte (n) + first polar body → secondary oocyte arrested at metaphase II and ovulated → if fertilization occurs, meiosis II completes → ovum (n) + second polar body.

Chromosome/DNA content transitions (conceptual)

• Premeiotic diploid cell: 2n (2c)
• After DNA replication (S phase): 2n (4c) — sister chromatids present
• After meiosis I: n (2c) — homologues separated, chromatids paired
• After meiosis II: n (1c) — sister chromatids separated, haploid gamete

Physiological and clinical notes (real-life relevance)

• Males produce millions of sperm per day (approx. 100–200 million/day); low sperm count (oligospermia) can cause male infertility.
• Females are born with a finite number of oocytes (~1–2 million at birth; ~300,000–400,000 at puberty) and normally ovulate ~400 times during reproductive life; fertility declines with age (notably after mid-30s) leading to menopause ~age 45–55.
• Assisted reproductive technologies (ART) like IVF retrieve multiple mature oocytes for fertilization in vitro; knowledge of oocyte arrest stages informs timing of ovulation induction and egg retrieval.

Fig 7 — Educational Diagram: Hormonal Regulation of Human Reproduction

Overview: Hormonal regulation of human reproduction coordinates gametogenesis, sexual behaviour, cyclic changes in the female reproductive tract and pregnancy. The hypothalamo–pituitary–gonadal (HPG) axis is central: the hypothalamus secretes GnRH (gonadotropin‑releasing hormone) which stimulates the anterior pituitary to release FSH (follicle stimulating hormone) and LH (luteinizing hormone). These gonadotropins act on the gonads (ovaries/testes) to produce gametes and steroid hormones (oestrogen, progesterone, testosterone) and peptide regulator inhibin. Steroid hormones and inhibin feedback on the hypothalamus and pituitary to regulate secretion.

Male hormonal regulation

• GnRH (pulsatile) → anterior pituitary → FSH and LH.
• LH acts on Leydig cells → testosterone (T) production. Testosterone promotes spermatogenesis (indirectly) and secondary sexual characteristics.
• FSH acts on Sertoli cells → supports spermatogenesis and produces inhibin.
• Negative feedback: Testosterone (mainly) and inhibin inhibit GnRH/FSH/LH to keep levels fairly constant. Thus males show relatively steady hormone levels and continuous sperm production.

Female hormonal regulation (cyclic)

The female reproductive cycle has two linked cycles: the ovarian cycle (follicular phase, ovulation, luteal phase) and the uterine/menstrual cycle (menstrual, proliferative, secretory phases). A typical cycle is ~28 days but varies.

• Early follicular phase (days 1–~13): GnRH pulses → FSH (slightly ↑) stimulates growth of several ovarian follicles. Growing follicles produce oestrogen (estradiol) and some inhibin. Rising oestrogen exerts negative feedback on GnRH/FSH/LH to limit further recruitment.
• Late follicular → pre‑ovulatory (around day 12–14): A dominant follicle emerges and secretes increasing estradiol. When estradiol rises above a threshold and is sustained for ~36–48 h, the feedback switches to positive on the pituitary, causing an LH surge (and smaller FSH surge). This LH surge triggers ovulation (rupture of the follicle and release of the secondary oocyte).
• Ovulation (day ~14): LH surge → enzymatic digestion of follicular wall → oocyte release. Basal body temperature (BBT) typically rises by ~0.3–0.5 °C after ovulation because of progesterone.
• Luteal phase (days 15–28): The ruptured follicle becomes corpus luteum → secretes progesterone and oestrogen. Progesterone prepares the endometrium for implantation (secretory phase) and exerts strong negative feedback on GnRH/FSH/LH to prevent new follicle growth. Inhibin from corpus luteum further suppresses FSH. If no fertilisation occurs, corpus luteum degenerates (corpus albicans), progesterone/oestrogen fall → withdrawal bleeding (menstruation) and release of inhibition so next cycle begins.
• Pregnancy: If fertilisation and implantation occur, trophoblast cells secrete hCG (human chorionic gonadotropin), which rescues the corpus luteum and maintains progesterone production until placental steroidogenesis takes over. High progesterone and oestrogen maintain uterine quiescence and support pregnancy. hCG is what pregnancy tests detect.

Feedback control—key principles

• Negative feedback: steroid hormones (testosterone, oestrogen, progesterone) and inhibin suppress GnRH and/or pituitary gonadotropin release to stabilise hormone levels.
• Positive feedback: transient—mid‑cycle high, sustained oestrogen levels cause positive feedback on the anterior pituitary to produce the LH surge that triggers ovulation.

Clinical/correlative points

• Combined oral contraceptives (oestrogen + progestin) provide steady steroid levels that maintain negative feedback on LH/FSH → prevent LH surge → no ovulation.
• Hormonal assays (serum FSH, LH, oestradiol, progesterone, testosterone, inhibin, hCG) are used in infertility, menopause evaluation and pregnancy monitoring.
• Conditions: PCOS often shows anovulation with elevated LH:FSH ratio (~2:1) and hyperandrogenism; Kallmann syndrome = deficient GnRH → hypogonadism/anosmia; lactational amenorrhea: high prolactin (from suckling) suppresses GnRH → temporary infertility.

Summary flow (simplified): Hypothalamus (GnRH pulses) → Pituitary (FSH, LH) → Gonads (gametogenesis + steroid hormones: oestrogen, progesterone, testosterone) → Feedback (negative or positive) to hypothalamus/pituitary.

Fig 8 — Educational Diagram: Ovarian and Menstrual Cycles

Overview
The ovarian and menstrual cycles are coordinated monthly processes that prepare a woman’s body for possible pregnancy. The ovarian cycle (events in the ovary) and the menstrual (uterine) cycle (changes in the endometrium) run concurrently and are controlled by hormones from the hypothalamus, pituitary and ovary.

Major hormones and control

• GnRH (hypothalamus) stimulates the anterior pituitary to release FSH and LH.
• FSH (follicle-stimulating hormone) promotes follicle growth and estrogen production by follicles.
• LH (luteinizing hormone) triggers ovulation and stimulates the corpus luteum to secrete progesterone (and some estrogen).
• Estrogen (primarily estradiol) and progesterone produced by the ovary exert negative and, at a high sustained level of estrogen just before ovulation, positive feedback on the pituitary/hypothalamus.

Ovarian cycle (≈ 28-day example)

• Follicular (pre-ovulatory) phase (day 1 to ~13): Several primordial follicles grow; one becomes dominant under FSH influence and secretes increasing estrogen.
• Ovulation (~day 14): High sustained estrogen from the dominant follicle causes a positive-feedback surge of LH (and some FSH) that causes rupture of the mature (Graafian) follicle and release of the oocyte.
• Luteal (post-ovulatory) phase (~day 15–28): The ruptured follicle becomes the corpus luteum, which secretes progesterone (and estrogen) to prepare the uterus for implantation. If pregnancy does not occur, the corpus luteum degenerates (after ~14 days), progesterone and estrogen fall, triggering menstruation.

Menstrual (uterine) cycle phases

• Menstrual phase (day 1–5): Fall in progesterone/estrogen causes shedding of the functional layer of endometrium — menstrual bleeding.
• Proliferative (pre-ovulatory) phase (day 6–14): Rising estrogen from developing follicles stimulates repair and proliferation (thickening) of the endometrium and development of glands and blood supply.
• Secretory (post-ovulatory) phase (day 15–28): Progesterone from the corpus luteum makes the endometrium secretory and receptive for implantation; glands secrete nutrients for a potential embryo.

Feedback patterns:

• Low-to-moderate estrogen → negative feedback on GnRH/FSH/LH (keeps hormone levels regulated during follicular growth).
• High sustained estrogen just before ovulation → positive feedback → LH surge → ovulation.
• Progesterone (and estrogen) from corpus luteum → negative feedback → suppresses new follicle development during luteal phase.

Outcome if fertilization occurs: The embryo produces hCG (human chorionic gonadotropin), which rescues the corpus luteum so it continues to secrete progesterone and maintain the endometrium, preventing menstruation.

Clinical/real-life relevance: Irregular cycles, anovulation (e.g., PCOS), amenorrhea, and luteal phase defects affect fertility. Combined oral contraceptives work by providing steady estrogen and progestin to suppress ovulation via negative feedback. Basal body temperature (BBT) and cervical mucus changes are used in natural family planning.

Fig 9 — Educational Diagram: Fertilization

Definition: Fertilization is the fusion of a male gamete (sperm) and a female gamete (ovum) to form a diploid zygote, restoring the chromosome number and initiating development of a new individual.

Where and when in humans: Human fertilization is internal and normally occurs in the ampullary region of the fallopian tube (uterine tube) within about 12–24 hours after ovulation. Sperm can remain viable in the female tract for up to 3–5 days; the ovum is viable for ~12–24 hours.

Major steps of fertilization:

• Transport and capacitation of sperm: After ejaculation into the vagina, sperm travel through the cervix and uterus to the fallopian tube. In the female tract they undergo capacitation (biochemical changes over several hours) that enable them to penetrate the egg.
• Penetration of the egg coverings: The ovum is surrounded by the cumulus oophorus (corona radiata) and the zona pellucida. Sperm first pass through the corona radiata aided by enzymes and motility, then bind to zona pellucida glycoproteins (notably ZP3). Binding triggers the acrosome reaction releasing hydrolytic enzymes that digest a path through the zona pellucida.
• Fusion of sperm and oocyte membranes: A single sperm fuses with the oocyte plasma membrane. The sperm nucleus, centrosome and other components enter the oocyte cytoplasm.
• Block to polyspermy: Immediately after the first sperm enters, the oocyte undergoes the cortical reaction (release of cortical granules) that modifies the zona pellucida (zona reaction), preventing entry of additional sperm.
• Completion of meiosis and pronuclei formation: The secondary oocyte completes meiosis II producing the female pronucleus and a second polar body. The sperm nucleus decondenses to form the male pronucleus.
• Amphimixis (syngamy): The male and female pronuclei move together, their nuclear envelopes break down and chromosomes mingle; this restores the diploid chromosome number and produces the zygote (single-cell embryo).
• Activation and early cleavage: Fertilization activates egg metabolism and triggers the first mitotic divisions (cleavage). The zygote undergoes successive divisions (2-cell, 4-cell, morula, blastocyst) as it moves toward the uterus for implantation.

Significance: Fertilization restores the diploid number (46 chromosomes in humans), determines sex (sperm carries X or Y), combines parental genes creating genetic variability, activates development and initiates embryogenesis.

Normal timing values (useful to remember):

• Ovum viability: ~12–24 hours after ovulation
• Sperm viability in female tract: up to 3–5 days (commonly cited as up to 5 days)
• Capacitation: several hours (typically 6–8 hours) in the female tract
• Fertilization typically occurs within 12–24 hours post-ovulation

Abnormal outcomes / clinical correlations: Ectopic (tubal) pregnancy—when the embryo implants in the fallopian tube instead of the uterus; polyspermy (if block fails) usually produces nonviable embryos; assisted reproductive techniques (IVF, ICSI) bypass or replicate natural fertilization steps.

Fig 10 — Educational Diagram: Early Embryonic Development

Overview

Early embryonic development is the sequence of events from fertilisation of the ovum to the formation of the basic body plan and primary germ layers. In humans this covers zygote formation, cleavage, morula, blastocyst formation, implantation, bilaminar disc formation and gastrulation (formation of ectoderm, mesoderm and endoderm).

Key stages and events (concise timeline)

• Fertilisation (Day 0): Sperm and oocyte nuclei fuse to form a diploid zygote, restoring 46 chromosomes.
• Cleavage (Day 1–3): Rapid mitotic divisions without overall growth produce smaller cells (blastomeres). Divisions approximate doubling of cell number.
• Morula (Day 3–4): A solid ball of ~16–32 blastomeres resembling a mulberry; cells begin compaction.
• Blastocyst formation (Day 4–5): Cavitation produces a fluid-filled blastocyst with an outer trophoblast (future placenta) and inner cell mass (embryoblast; future embryo).
• Hatching (Day 5–6): Blastocyst escapes the zona pellucida and is capable of implanting.
• Implantation (Day 6–12): Trophoblast attaches to and invades the endometrium; syncytiotrophoblast forms and secretes hCG; implantation completes by ~day 12.
• Bilaminar disc (Week 2): Inner cell mass differentiates into epiblast and hypoblast. Amniotic cavity and primary yolk sac form.
• Gastrulation (beginning ~Day 15 / Week 3): Primitive streak forms on the epiblast; epiblast cells ingress and create the three germ layers—ectoderm, mesoderm, endoderm—which give rise to all tissues/organs.

Cellular & molecular highlights

• Trophoblast differentiation: Cytotrophoblast (inner cell layer) and syncytiotrophoblast (multinucleated outer layer) invade the uterine wall and initiate maternal-fetal interface.
• Embryoblast differentiation: Epiblast gives rise to the embryo proper; hypoblast contributes to extraembryonic structures like the yolk sac.
• Germ layers fate: Ectoderm → nervous system and epidermis; Mesoderm → muscle, bone, circulatory system; Endoderm → gut lining and associated organs.
• Signalling & patterning: Gradients of growth factors (e.g., BMP, Wnt, FGF) and the primitive streak coordinate cell fate and body axes (anteroposterior, dorsoventral).

Clinical relevance and checkpoints

• Implantation window: Successful implantation requires synchrony between a competent blastocyst and a receptive endometrium (clinical relevance to IVF/ET timing).
• hCG production: Secreted by syncytiotrophoblast soon after implantation; basis for pregnancy tests.
• Gastrulation errors: Cause severe congenital malformations (e.g., neural tube defects; folic acid supplementation before conception reduces risk).
• Ectopic pregnancy: Implantation outside uterus (commonly in fallopian tube) — a life-threatening condition requiring prompt management.

Simple summary

Early embryonic development transforms a single fertilised cell into a multicellular embryo with distinct germ layers and the start of body plan organization. It is highly regulated in time and space; disruptions at different steps lead to distinct clinical consequences.

Fig 11 — Educational Diagram: Implantation and Placenta

Overview
Implantation is the process by which the blastocyst attaches to and invades the uterine lining (endometrium) and establishes the maternal–fetal interface. The placenta is a temporary fetomaternal organ that develops from trophoblast and maternal tissues, enabling metabolic, respiratory, excretory and endocrine support to the developing embryo and fetus throughout pregnancy.

Timing & early events
Fertilization occurs in the fallopian tube (day 0). The zygote undergoes cleavage (morula by day 3–4) and forms a blastocyst (~day 5). Implantation usually begins around day 6–7 after fertilization and is typically completed by the end of the second week.

Steps of implantation

• Apposition: the blastocyst orients and comes into loose contact with the endometrial epithelium (usually posterior uterine wall).
• Adhesion: cell adhesion molecules (integrins, selectins) mediate stronger attachment of the trophoblast to endometrial cells.
• Invasion: trophoblast differentiates and invades the endometrium. Cytotrophoblasts proliferate and fuse to form syncytiotrophoblasts that digest endometrial tissue using proteolytic enzymes, forming lacunae (maternal blood spaces).

Trophoblast differentiation and early placental formation
Trophoblast differentiates into:

• Cytotrophoblast (inner cellular layer) — mitotically active cells.
• Syncytiotrophoblast (outer multinucleated layer) — invades maternal tissue and secretes human chorionic gonadotropin (hCG).

Placenta: structure

• Fetal part: formed by chorionic villi on the chorionic (fetal) plate; connected to the fetus by the umbilical cord (normally two umbilical arteries and one vein).
• Maternal part: decidua basalis — shows lobules called cotyledons (the same placenta has multiple cotyledons on the maternal surface).

Functions of placenta

• Exchange: O2 and CO2 (gas exchange), nutrients (glucose, amino acids, fatty acids), and waste products (urea, creatinine).
• Endocrine: secretes hCG (early), then progesterone and estrogens (placenta takes over steroid production by ~8–10 weeks; luteal–placental shift). Also secretes human placental lactogen (hPL), relaxin and others.
• Immune & barrier: transfers maternal IgG antibodies to provide passive immunity; blocks most maternal immune rejection but is not a perfect barrier (some pathogens/drugs cross).
• Metabolic & storage: synthesizes glycogen, cholesterol; stores some nutrients.

Physiological adaptations
The placenta has a huge branching surface area and very thin diffusion barrier to maximize transfer. Spiral arteries are remodeled by invading trophoblast to increase blood flow to intervillous spaces. Any failure in proper remodeling can lead to complications like preeclampsia.

Clinical correlations / common problems

• Ectopic pregnancy: implantation outside the uterine cavity (most commonly fallopian tube) — medical emergency.
• Molar pregnancy: abnormal trophoblastic proliferation (hydatidiform mole) — high hCG, potential malignancy.
• Placenta previa: placenta partially/fully covers the cervical os → bleeding, needs obstetric management.
• Placental abruption: premature separation of placenta from uterine wall → fetal/maternal distress.
• Drug/toxin transfer: nicotine, alcohol, many drugs, and some infections (e.g., rubella, cytomegalovirus) cross placenta and harm the fetus.

Immunology
The decidua produces immune-modulatory factors to prevent rejection of semi-allogenic embryo; maternal IgG is selectively transported across placenta (provides neonatal immunity); IgM does not cross.

Takeaway points (concise)

• Implantation: blastocyst attachment → trophoblast invasion (syncytiotrophoblast) → lacunae and early circulation.
• Placenta: fetomaternal organ for exchange, endocrine function and immune protection; human placenta is hemochorial and highly efficient.
• Placenta produces hCG early, then steroid hormones (progesterone and estrogens) increase through pregnancy.

Fig 12 — Educational Diagram: Fetal Membranes and Amniotic Fluid

Overview
Fetal membranes are extra‑embryonic structures that surround and protect the developing embryo/fetus. Major membranes are the amnion, chorion, yolk sac and allantois. The amniotic cavity contains amniotic fluid, a clear, slightly alkaline fluid that cushions the fetus and is essential for normal development.

Formation (brief timeline)

• Blastocyst stage: trophoblast differentiates into cytotrophoblast and syncytiotrophoblast (future fetal contribution to placenta).
• Amnion: forms from epiblast cells that line the amniotic cavity; creates the amniotic sac around the embryo.
• Yolk sac: primary yolk sac (from hypoblast) gives way to the secondary (definitive) yolk sac; important in early nutrition and primitive blood cell formation.
• Allantois: an outpouching of the hindgut contributing to early blood vessels of the umbilical cord and urinary bladder in the embryo.
• Chorion: formed by trophoblast + extra‑embryonic mesoderm; chorionic villi form and participate in placenta formation.

Structure and relationships

• Amnion: thin membrane directly surrounding the amniotic cavity and fluid; inner layer of the fetal sac.
• Chorion: outer membrane; fetal part of the placenta is formed from chorionic villi.
• Yolk sac & allantois: small, transient structures; yolk sac important early, allantois contributes to umbilical vessels.

Amniotic fluid — composition & sources

• Composition: mostly water with electrolytes, proteins, urea, creatinine, fetal cells (desquamated epithelial cells), lanugo hair and vernix caseosa; contains growth factors and immune components.
• Sources during pregnancy: early secretion from amniotic membrane and maternal plasma transudation; after first trimester the main contributors are fetal urine and lung secretions; fetus also swallows fluid, which participates in GI and lung development.

Functions

• Mechanical protection: cushions fetus from shocks and prevents external pressure.
• Allows fetal movements: essential for musculoskeletal development and prevents adhesions.
• Maintains constant temperature around fetus.
• Prevents amnion‑chorion adhesion to fetal parts and permits normal growth.
• Facilitates lung development: fetal breathing movements and lung fluid regulate lung maturation.
• Route for biochemical exchange and fetal waste (temporary reservoir) — fetal urine restitution.

Clinical importance

• Rupture of membranes (ROM): 'water breaks'—rupture may be at term (normal labour) or preterm (risks of infection and preterm birth).
• Amniocentesis: sampling amniotic fluid (after ~15–16 weeks) for fetal genetic testing, biochemical tests and fetal lung maturity. Small risk of miscarriage.
• Abnormal volumes: oligohydramnios (low volume), often associated with fetal renal agenesis or leak; polyhydramnios (high volume), associated with maternal diabetes or fetal GI/neurological anomalies impairing swallowing.
• Meconium in amniotic fluid: may indicate fetal distress; risk of meconium aspiration syndrome at birth.

Key points to remember (CBSE level)

• Amnion = inner membrane + contains amniotic fluid. Chorion = outer membrane, contributes to placenta.
• Fetal urine is the major contributor to amniotic fluid after first trimester.
• Amniotic fluid volume rises with gestational age, peaks in late third trimester (roughly several hundred millilitres to ~0.8–1 L) and is monitored by ultrasound.

Fig 13 — Educational Diagram: Pregnancy and Prenatal Development

Pregnancy and Prenatal Development

Pregnancy is the period from fertilization of the ovum to the birth of the baby. Prenatal development is the sequence of events by which a single-celled zygote develops into a fully formed baby. Clinically pregnancy is measured from the first day of the last menstrual period (LMP) — this is called gestational age. The period is conventionally divided into trimesters and, developmentally, into the embryonic period (first 8 weeks after fertilization) and the fetal period (9 weeks to birth).

1. Events from fertilization to implantation

- Fertilization: Fusion of sperm and ovum in the ampullary region of the fallopian tube to form a diploid zygote.

- Cleavage: Rapid mitotic divisions form a morula (16–32 cells) as the conceptus moves down the tube.

- Blastocyst formation: A fluid-filled cavity forms producing an outer trophoblast (future placenta) and an inner cell mass (embryoblast — future embryo). By ~5–6 days a blastocyst forms.

- Implantation: Blastocyst attaches to and embeds in the endometrium (usually 6–10 days after fertilization). Trophoblast differentiates into cytotrophoblast and syncytiotrophoblast that invade maternal tissue and establish early placental contact.

2. Embryonic period (organogenesis, weeks 3–8 after fertilization)

- This is the critical period for organ formation. The three germ layers are formed (ectoderm, mesoderm, endoderm).

- Major events: formation of the primitive streak, neurulation (neural tube formation), heart tube and early circulation, limb buds, facial features and basic organ primordia.

- Most congenital malformations (structural defects) arise from insults during this period (teratogens, infections, severe maternal malnutrition).

3. Fetal period (weeks 9 to birth)

- Growth and maturation of organs formed during the embryonic period. Rapid increase in size and weight, development of functional maturity (lungs, brain connectivity, kidney function).

- By the end of the first trimester many basic structures are present; viability (survival outside womb with intensive care) increases progressively after ~24 weeks gestation.

4. Placenta, membranes and fetal–maternal exchange

- Placenta develops from trophoblast and maternal tissue; functions as site for gas exchange, nutrient uptake, waste elimination, hormone production (hCG early, progesterone, estrogens), and an immunological barrier.

- Umbilical cord contains two arteries (carry deoxygenated blood from fetus) and one vein (carry oxygenated blood to fetus).

5. Hormonal regulation of pregnancy

- hCG (human chorionic gonadotropin): secreted by syncytiotrophoblast; maintains corpus luteum and progesterone production in early pregnancy; basis for pregnancy tests. hCG rises rapidly in early pregnancy (doubling ~48–72 hours) then plateaus.

- Progesterone and estrogens: produced initially by corpus luteum (supported by hCG) and later by placenta; progesterone maintains endometrium and suppresses uterine contractions; estrogens promote uterine growth and blood flow.

6. Maternal physiological changes

- Cardiovascular: increased blood volume (up to 30–50%), increased cardiac output, slight drop in peripheral resistance.

- Respiratory: increased tidal volume and minute ventilation.

- Metabolic and renal: increased nutritional needs, increased glomerular filtration rate.

- Immune: modulated to tolerate the semi-allogenic fetus; some increased susceptibility to certain infections.

7. Prenatal care and diagnostics

- Antenatal care: early booking, nutritional counseling (folic acid, iron, balanced diet), immunizations (as advised), monitoring maternal BP, weight, urine and fetal growth.

- Screening and diagnostic tests: first-trimester ultrasound (dating, nuchal translucency), maternal serum marker screening, non-invasive prenatal testing (NIPT) using cell-free fetal DNA, invasive tests when indicated — chorionic villus sampling (CVS, ~10–13 weeks) and amniocentesis (~15–20 weeks) for chromosomal and genetic diagnosis.

8. Teratogens and prevention

- Teratogens (agents that can disturb development): medicines (e.g., thalidomide), infections (rubella, cytomegalovirus, Zika), alcohol (fetal alcohol spectrum disorders), tobacco (low birth weight), ionizing radiation, uncontrolled diabetes, extreme malnutrition.

- Prevention: preconception counseling, immunization (rubella before pregnancy), folic acid supplementation (400 μg daily preconception and early pregnancy to reduce neural tube defects), avoidance of known teratogens, good antenatal care.

9. Outcome measures and complications

- Important outcomes: gestational age at birth, birth weight, APGAR score, congenital anomalies, perinatal morbidity and mortality.

- Common complications: ectopic pregnancy (implantation outside uterus — medical emergency), preeclampsia (hypertension with proteinuria), gestational diabetes, intrauterine growth restriction (IUGR), preterm labor.

Concise summary: Pregnancy progresses from fertilization → implantation → embryonic organogenesis (weeks 3–8) → fetal growth and maturation (week 9 to birth). The placenta and pregnancy hormones sustain development. Prevention of teratogenic exposures and good antenatal care are key to healthy prenatal development.

Fig 14 — Educational Diagram: Parturition (Childbirth)

Definition: Parturition (childbirth) is the process by which the full‑term fetus, fetal membranes and placenta are expelled from the uterus. It is triggered by coordinated maternal and fetal endocrine signals that cause rhythmic uterine contractions, cervical dilatation and delivery.

Key events and mechanism:

• Endocrine preparation: Late pregnancy shows an increase in estrogen and a relative decline in progesterone activity (functional progesterone withdrawal). Estrogen up‑regulates uterine oxytocin receptors and gap junctions between myometrial cells, increasing uterine excitability.
• Fetal signal: Maturation of the fetal hypothalamic–pituitary–adrenal (HPA) axis raises fetal cortisol. Fetal cortisol increases placental estrogen synthesis and prostaglandin production, which help initiate labor.
• Onset of labor: Rising prostaglandins (esp. PGE2, PGF2α) and maternal oxytocin (from posterior pituitary) cause coordinated myometrial contractions. Stretch of the cervix and uterus by contractions stimulates maternal oxytocin release — a positive feedback loop (Ferguson reflex).
• Rupture of membranes: Often occurs during labor (spontaneous rupture of membranes) releasing amniotic fluid and sometimes accelerating labor.

Stages of labor:

• First stage (dilation): From onset of true labor to full cervical dilatation (10 cm). Subdivided into latent (slow dilatation) and active phase (faster dilatation).
• Second stage (expulsion): From full dilatation to delivery of the baby. Strong expulsive contractions and maternal pushing.
• Third stage (placental): Delivery of the placenta and membranes; uterine contraction reduces bleeding and aids placental separation.

Physiological changes and adaptations:

• Uterine muscles contract in coordinated waves; cervical collagen is remodelled (softening, effacement) to allow dilatation.
• Relaxin softens pelvic ligaments and pubic symphysis, aiding passage of the fetus.
• Fetal adaptations: compressive forces and transient reductions in oxygen are expected; obstetric monitoring (fetal heart rate) detects distress.

Clinical aspects: Induction of labor may be done with prostaglandins or intravenous oxytocin. Analgesia (epidural) is commonly used. Cesarean section is performed when vaginal delivery is unsafe (fetal distress, malpresentation, obstructed labor).

Complications: Dystocia (prolonged or obstructed labor), postpartum hemorrhage (due to uterine atony), uterine rupture, fetal distress, infection if membranes rupture long before delivery.

Summary (flow): Fetal lung maturation and cortisol → increased placental estrogen & prostaglandins + decreased progesterone effect → ↑ oxytocin receptors on myometrium → uterine contractions → cervical dilatation → fetal expulsion → placental separation.

Fig 15 — Educational Diagram: Lactation

Definition: Lactation is the production and secretion of milk by the mammary glands to nourish the newborn. It includes development of mammary tissue, initiation of milk secretion, maintenance of milk production, and milk ejection.

Phases:

• Mammogenesis – development of mammary glands during puberty and pregnancy under influence of estrogen, progesterone, prolactin and placental hormones.
• Lactogenesis – onset of milk secretion. Lactogenesis I occurs in late pregnancy when secretory differentiation begins; Lactogenesis II begins after delivery when copious secretion starts as progesterone falls.
• Galactopoiesis – maintenance of established milk production, largely driven by frequent removal of milk (suckling) and hormonal support (prolactin, insulin, cortisol, thyroid hormones).
• Milk ejection (Let-down) – neuroendocrine reflex causing contraction of myoepithelial cells around alveoli mediated by oxytocin, ejecting milk into ducts for suckling.

Cellular basis and mechanism: Mammary alveoli are the secretory units lined by epithelial cells that synthesize milk components and surrounded by myoepithelial cells. Suckling stimulates sensory nerves in the nipple; this signal travels to the hypothalamus and anterior/posterior pituitary. Prolactin from anterior pituitary promotes synthesis of milk components in alveolar cells. Oxytocin from posterior pituitary causes myoepithelial contraction and milk ejection. Dopamine acts as a prolactin-inhibiting factor; suckling reduces dopamine release, enabling prolactin pulses.

Hormonal regulation summary: - During pregnancy: high estrogen and progesterone stimulate ductal growth and alveolar differentiation but inhibit milk secretion despite high prolactin. Human placental lactogen assists development. - At birth: expulsion of placenta causes abrupt fall in estrogen and progesterone, releasing inhibition and allowing prolactin to induce milk synthesis. - Postpartum: suckling-induced prolactin pulses maintain milk synthesis; oxytocin causes milk ejection.

Milk composition (typical human mature milk, approximate): Water ~87%; lactose ~6.8–7.0 g/100 ml; lipids ~3.5–4.5 g/100 ml; protein ~1.0–1.3 g/100 ml; minerals and vitamins in small amounts; abundant immunoglobulin A (secretory IgA) and leukocytes. Energy ~65–70 kcal/100 ml. Colostrum (first few days) is richer in protein, immunoglobulins and lower in fat and lactose.

Advantages of breastfeeding: Provides optimal nutrition, passive immunity (IgA protects gut and respiratory tract), reduces neonatal infections, promotes mother-infant bonding, decreases postpartum bleeding (oxytocin effect), may reduce maternal risk of certain cancers, and provides a natural temporary contraception if Lactational Amenorrhea Method (LAM) conditions are met.

Common clinical points: - Let-down reflex may be inhibited by stress; repeated proper suckling and comfortable positioning help. - Problems: engorgement, cracked nipples, mastitis (infection), inadequate milk supply, galactorrhea (abnormal milk flow due to prolactin excess).

Public health recommendation: Exclusive breastfeeding for the first six months is recommended by WHO/UNICEF, with continued breastfeeding along with complementary foods up to 2 years or beyond.

Fig 16 — Educational Diagram: Contraception and Family Planning

Overview
Contraception and family planning are methods and practices used to prevent unwanted pregnancy, plan the number and spacing of children, and protect reproductive health. Methods range from behavioural and barrier methods to hormonal, intrauterine devices, and permanent sterilization.

Main categories and how they work

• Barrier methods: Physically block sperm from reaching the egg. Examples: male condom, female condom, diaphragm. Condoms also protect against sexually transmitted infections (STIs).
• Hormonal methods: Use synthetic hormones (estrogen and/or progestin) to suppress ovulation, thicken cervical mucus, and alter the endometrium. Examples: combined oral contraceptive pills, progestin-only pills, injectables, implants, transdermal patch. They require medical guidance and have systemic effects.
• Intrauterine devices (IUDs): T-shaped devices placed inside the uterus. Copper IUDs (e.g., Copper-T) are spermicidal and impair sperm motility; hormonal IUDs release progestin to thicken cervical mucus and sometimes suppress endometrium/ovulation.
• Emergency contraception: Pills (levonorgestrel or ulipristal) or copper IUD insertion after unprotected intercourse to prevent or delay ovulation or interfere with implantation. Should be used as soon as possible after exposure.
• Permanent methods (sterilization): Surgical procedures that permanently prevent conception: tubectomy (female sterilization) and vasectomy (male sterilization). They block or cut the reproductive ducts.
• Natural and fertility-awareness methods: Calendar/rhythm method, basal body temperature, cervical mucus (Billings) method, and lactational amenorrhea method (LAM). They rely on identifying fertile days and avoiding intercourse or using protection on those days.
• Spermicides: Chemical agents (gels, foams, suppositories) that kill or immobilize sperm; often used with barrier methods.

Effectiveness and failure
Effectiveness varies by method and by correct vs typical use. "Perfect use" refers to consistent, correct use; "typical use" accounts for human error. Sterilization, implants, and IUDs are among the most effective; condoms and pills are highly effective when used correctly but have higher typical-use failure rates. Natural methods have higher failure rates unless followed rigorously.

Health, advantages and side effects
Contraception has major public health benefits: reduces unintended pregnancies, maternal and infant mortality, and allows couples to space births. Side effects vary by method: hormonal methods can cause nausea, mood changes, irregular bleeding; IUDs may cause heavier periods (copper) or spotting (hormonal); surgical methods are invasive and largely irreversible. Counselling should balance benefits and risks and consider contraindications (e.g., some smokers over 35 should avoid combined pills).

Family planning programs
Family planning includes education, access to a range of contraceptive options, and reproductive health services. Policies aim to increase contraceptive prevalence, reduce unmet need for contraception, and improve maternal and child health.

Key practical points for students

• Choose method based on health, desired duration, effectiveness, side effects, and STI protection needs.
• Emergency contraception is not a regular method; it reduces risk after unprotected intercourse but is less reliable than ongoing methods.
• Dual protection (condom + another contraceptive) can prevent both pregnancy and STIs.

Fig 17 — Educational Diagram: Assisted Reproductive Technologies (ART)

Definition: Assisted Reproductive Technologies (ART) are medical procedures used to treat human infertility by handling eggs, sperm, or embryos outside the body and/or using third‑party donors or a surrogate mother.

Major types and short descriptions:

• In Vitro Fertilization (IVF): Oocytes are collected from the stimulated ovary, fertilized with sperm in the laboratory, embryos are cultured for a few days and then transferred to the uterus.
• Intracytoplasmic Sperm Injection (ICSI): A single sperm is injected directly into the oocyte cytoplasm — used mainly for severe male factor infertility.
• Gamete Intrafallopian Transfer (GIFT): Eggs and sperm are placed together into a fallopian tube so fertilization can occur in vivo. (Less commonly used today.)
• Zygote Intrafallopian Transfer (ZIFT): A zygote (fertilized egg) is transferred into the fallopian tube — combines in vitro fertilization with tubal transfer.
• Intrauterine Insemination (IUI) / Donor Insemination: Processed sperm is placed directly in the uterine cavity around ovulation to increase chance of fertilization.
• Cryopreservation: Freezing and storage of sperm, oocytes or embryos for future use (vitrification commonly used for eggs/embryos).
• Use of donors and surrogacy: Donor eggs, donor sperm, or surrogates (gestational carriers) may be used when one partner cannot provide gametes or carry a pregnancy.

Typical IVF/ICSI procedure (stepwise):

1. Ovarian stimulation: Hormonal drugs (FSH, sometimes with LH) are given to stimulate multiple follicle development.
2. Monitoring: Ultrasound and hormonal assays (estradiol) monitor follicular growth.
3. Ovulation trigger: hCG or GnRH agonist given to mature oocytes at the right time.
4. Oocyte retrieval (aspiration): Transvaginal ultrasound‑guided follicular aspiration under mild anesthesia.
5. Sperm preparation: Semen is processed to concentrate motile sperm.
6. Fertilization: Conventional IVF (co‑incubation of eggs + sperm) or ICSI (single sperm injected into each egg).
7. Embryo culture: Embryos are cultured 2–6 days and assessed for quality.
8. Embryo transfer: One or more embryos placed into uterine cavity (ideally single embryo to reduce multiples).
9. Luteal support: Progesterone (and sometimes estrogens) given to support implantation.
10. Pregnancy test and follow up: Serum β‑hCG measured ~11–14 days after embryo transfer; ultrasound to confirm gestational sac and fetal heartbeat.

Indications: Tubal block or damage, severe male factor infertility (low count, poor motility), unexplained infertility, endometriosis, advanced maternal age, genetic disorders (with preimplantation genetic testing), single women or same‑sex couples wanting a child.

Factors affecting success: Maternal age and ovarian reserve, sperm quality, embryo quality (chromosomal normality), uterine receptivity, stimulation protocol, clinic experience.

Complications and risks: Multiple pregnancy (if multiple embryos transferred), ovarian hyperstimulation syndrome (OHSS), ectopic pregnancy, procedure‑related infection, psychological stress, and financial cost.

Ethical, social and legal considerations: Use of donor gametes or surrogates raises questions of parentage, anonymity, consent, rights of donor/surrogate and child, disposition of unused embryos, access and equity, and religious/cultural acceptability. Many countries regulate number of embryos transferred, donor screening, and surrogacy contracts.

Advances and special techniques: ICSI for severe male infertility, vitrification for improved egg/embryo survival, preimplantation genetic testing (PGT) to screen embryos for chromosomal or single‑gene disorders, assisted hatching for implantation failure, and time‑lapse embryo imaging to select best embryos.

Summary: ART provides multiple medically and ethically complex options to help people conceive when natural conception is not possible or carries high risk. Success depends on biological factors (especially maternal age), clinical technique, and appropriate selection of treatment type.

Fig 18 — Educational Diagram: Reproductive Health and Sexually Transmitted Diseases (STDs)

Reproductive health means complete physical, mental and social well‑being in all matters relating to the reproductive system. It implies the ability to have a responsible, satisfying and safe sex life, the capability to reproduce, and the freedom to decide if, when and how often to do so. Key components include family planning and contraception, safe pregnancy and childbirth (maternal health), prevention and management of reproductive tract infections (RTIs) and sexually transmitted diseases (STDs), infertility diagnosis and care, sexual education, and reproductive rights.

Contraception and family planning: Methods are classified as temporary (barrier methods like condoms, hormonal pills, IUCDs) and permanent (tubectomy, vasectomy). Contraception helps avoid unwanted pregnancies, reduces maternal mortality and allows spacing of births. Condoms also reduce transmission of STDs.

Maternal and neonatal care: Antenatal care, screening for infections (HIV, syphilis, hepatitis B), tetanus immunization, safe delivery and postnatal care reduce risks to mother and baby. Prevention of mother‑to‑child transmission (PMTCT) of HIV uses antiretroviral therapy (ART), appropriate delivery planning and infant feeding guidance.

Infertility and assisted reproduction: Infertility is the inability to conceive after one year of unprotected intercourse. Causes may be male (low sperm count, motility) or female (anovulation, blocked fallopian tubes). Investigations include semen analysis, hormonal assays, hysterosalpingography. Treatments range from medical therapy to assisted reproductive technologies (ART) such as in vitro fertilization (IVF).

Sexually transmitted diseases (STDs) / Sexually transmitted infections (STIs): STDs are infections transmitted primarily through sexual contact. Common agents and features:

• Bacterial: Gonorrhoea (Neisseria gonorrhoeae) — urethral/vaginal discharge, dysuria; Chlamydia (Chlamydia trachomatis) — often asymptomatic, can cause pelvic inflammatory disease (PID); Syphilis (Treponema pallidum) — stages: primary (chancre), secondary (rash), latent, tertiary (gummas, neurosyphilis).
• Viral: HIV — progressive immune deficiency; Genital herpes (HSV‑1/2) — painful vesicles; Human papillomavirus (HPV) — warts, some types cause cervical cancer; Hepatitis B — liver infection, sexual and blood transmission.
• Protozoal / Fungal: Trichomoniasis (Trichomonas vaginalis) — frothy discharge; Candidiasis (Candida) — itching and white discharge (often not primarily sexually transmitted).

Diagnosis: Clinical history and examination plus laboratory tests: Gram stain, culture, nucleic acid amplification tests (NAAT/PCR) for gonorrhoea and chlamydia, VDRL/RPR and TPHA for syphilis, ELISA/rapid tests for HIV and hepatitis B surface antigen, Pap smear for cervical cytology, HPV DNA testing. In low‑resource settings a syndromic approach (treating on the basis of symptoms) is sometimes used.

Treatment: Timely, appropriate therapy prevents complications and further spread. Examples: penicillin for syphilis (IM benzathine penicillin), ceftriaxone (+/− azithromycin) for uncomplicated gonorrhoea (resistance is rising), doxycycline or azithromycin for chlamydia, metronidazole for trichomoniasis, acyclovir for genital herpes (suppression & outbreak control), ART for HIV (combination antiretroviral therapy to control the virus). Partner notification and treatment is essential.

Complications: Untreated STDs can cause PID, infertility, ectopic pregnancy, chronic pelvic pain, neonatal infection (congenital syphilis, neonatal herpes, perinatal HIV), increased risk of HIV acquisition, and certain cancers (HPV → cervical cancer).

Prevention and public health measures:

• Safe sex practices: correct and consistent condom use, limiting number of sexual partners, mutual monogamy with uninfected partner.
• Vaccination: HPV vaccine (prevents HPV types that cause cervical cancer and genital warts); hepatitis B vaccine.
• Screening and early treatment: routine antenatal screening for HIV, syphilis and hepatitis B; Pap smear/HPV testing for cervical cancer screening.
• Education and counselling: sex education in schools, adolescent-friendly services, stigma reduction and reproductive rights awareness.
• Programmatic steps: contact tracing, partner notification, accessible testing and free/affordable treatment, needle‑safety measures.

Ethical, social and legal aspects: Reproductive health care must respect confidentiality, informed consent and human rights. Addressing gender inequality, reducing stigma around STDs, and ensuring adolescents’ access to accurate information are important for effective control.

Summary: Reproductive health is broad — from contraception and safe pregnancy to preventing and treating STDs. Combining biomedical measures (vaccines, diagnostics, medicines) with education, social support and health services reduces disease burden and improves individual and public health outcomes.

Fig 19 — Educational Diagram: Infertility: Causes and Management

Definition: Infertility is the inability of a sexually active, non-contracepting couple to achieve pregnancy within 1 year. It is classified as primary (no previous pregnancy) or secondary (failure to conceive after a previous pregnancy).

Basic facts

About 10–15% of couples are affected. Infertility is due to male factors in ~30–40% of cases, female factors in ~40–50%, both partners in ~10–20% and unexplained in ~10–15%.

Causes — Male

• Spermatogenesis problems: Azoospermia (no sperm), oligospermia (low count), asthenozoospermia (poor motility), teratozoospermia (abnormal morphology). Causes include genetic defects, undescended testes, heat exposure, varicocele, endocrine disorders (hypogonadism), infections (mumps orchitis), systemic illness and drugs.
• Obstruction: Blockage of the vas deferens or ejaculatory ducts (congenital or post-infectious/surgical).
• Sexual/ejaculatory disorders: Retrograde ejaculation, erectile dysfunction.
• Lifestyle & environmental: Smoking, alcohol, anabolic steroids, toxins, radiation, high scrotal temperature.

Causes — Female

• Ovulatory disorders: Anovulation or irregular ovulation as in PCOS (polycystic ovary syndrome), hypothalamic amenorrhoea, premature ovarian insufficiency. Age-related decline in ovarian reserve is a major factor.
• Tubal/pelvic pathology: Blocked or damaged fallopian tubes due to pelvic inflammatory disease (PID), previous surgery, or endometriosis. Tubal blockage increases ectopic pregnancy risk.
• Uterine & cervical factors: Fibroids, congenital anomalies (septate uterus), endometrial scarring (Asherman’s syndrome), hostile cervical mucus, immunological factors.
• Endometriosis: Ectopic endometrial tissue causing adhesions, inflammation and impaired fertility.

Investigation / Diagnosis

• Male: Detailed history and physical exam, two semen analyses (WHO criteria), hormonal assays (FSH, LH, testosterone), scrotal ultrasound, genetic tests (karyotype, Y microdeletions) if indicated.
• Female: Menstrual and ovulatory assessment (basal body temperature, mid-luteal progesterone, ovulation kits), hormonal profile (FSH, LH, prolactin, TSH, AMH), pelvic ultrasound, hysterosalpingography (HSG) to check tubal patency, hysteroscopy and diagnostic laparoscopy (endometriosis, adhesions).
• Couple-level: Infectious screening (STIs), immunological tests and chromosomal studies when recurrent pregnancy loss or severe abnormalities are present.

Management

Treatment is guided by cause, duration, age and couple preference. General measures include addressing lifestyle factors (stop smoking, reduce alcohol, weight management, avoid heat/toxins).

• Medical therapy:
  • Ovulation induction: Clomiphene citrate, letrozole (first-line for PCOS), gonadotropins (FSH/LH) for stimulation.
  • Male endocrine disorders: Testosterone only when indicated; treat pituitary causes appropriately.
  • Treatment of infections and correction of endocrine abnormalities (e.g., thyroid, hyperprolactinemia).
• Surgical therapy:
  • Varicocelectomy (improves semen parameters in some men).
  • Laparoscopic surgery for endometriosis, tubal adhesiolysis, correction of uterine anomalies (metroplasty) and removal of fibroids when indicated.
  • Microsurgical reconstruction for vas deferens or tubal blockage in selected cases.
• Assisted Reproductive Technologies (ART):
  • Intrauterine insemination (IUI): Washed sperm placed into the uterus—used for mild male factor or unexplained infertility.
  • In vitro fertilization (IVF): Ovarian stimulation, egg retrieval, fertilisation and embryo transfer.
  • Intracytoplasmic sperm injection (ICSI): Single sperm injected into oocyte—used for severe male factor or previous IVF fertilisation failure.
  • Donor gametes (sperm or egg), embryo donation and surrogacy where indicated legally and ethically.
  • Cryopreservation of sperm, eggs and embryos for fertility preservation (before chemo/age-related decline).

Outcomes & Prognosis

Prognosis depends on cause and age. Female age is the single most important predictor—fertility declines markedly after 35 years due to reduced oocyte number and quality. ART success rates vary with age and clinic; multiple cycles often required. Counseling for realistic expectations, psychosocial support and ethical/legal considerations for donor/surrogacy arrangements are essential.

Prevention & Public health

Prevent STIs by safe sex, timely treatment of reproductive tract infections, avoid unnecessary pelvic surgery, maintain healthy lifestyle, screen and treat varicocele/cryptorchidism early and provide fertility education about age-related decline.

Fig 20 — Educational Diagram: Reproductive System Disorders and Abnormalities

Overview

Reproductive system disorders and abnormalities affect structure or function of male and female reproductive organs, hormone balance, gametogenesis, fertilization, implantation or pregnancy. They arise from genetic causes (chromosomal abnormalities), hormonal imbalances, infections, anatomical defects, tumors, lifestyle and environmental factors. These conditions can lead to infertility, miscarriage, ectopic pregnancy, congenital defects and other health problems.

Classification & Causes

• Genetic/chromosomal abnormalities: e.g., Turner syndrome (45,X), Klinefelter syndrome (47,XXY), autosomal trisomies (Down syndrome) — affect development and fertility.
• Hormonal/endocrine disorders: e.g., PCOS (polycystic ovary syndrome) — hyperandrogenism and anovulation; hypothyroidism or hyperprolactinemia — can disturb menstrual cycle and fertility.
• Anatomical/structural problems: e.g., blocked fallopian tubes, uterine fibroids, congenital malformations, varicocele — interfere with gamete transport or implantation.
• Infections and inflammatory diseases: e.g., pelvic inflammatory disease (PID), sexually transmitted infections (chlamydia, gonorrhoea) — cause scarring and infertility.
• Neoplasms: e.g., ovarian or testicular tumours, cervical cancer (often HPV-associated).
• Pregnancy-related abnormalities: e.g., ectopic pregnancy, spontaneous abortion (miscarriage), hydatidiform mole.
• Lifestyle/environmental: obesity, smoking, alcohol, radiation, endocrine-disrupting chemicals affecting fertility.

Key Disorders — Short Explanations

• Polycystic Ovary Syndrome (PCOS): Hormonal disorder with multiple ovarian follicles, irregular/absent ovulation, high androgens. Leads to infertility, irregular menses, hirsutism, insulin resistance.
• Endometriosis: Endometrial tissue outside uterus (ovaries, peritoneum). Painful menses, painful intercourse, infertility due to scarring/adhesions.
• Pelvic Inflammatory Disease (PID): Infection of upper female reproductive tract often from STIs — causes scarring of fallopian tubes and ectopic pregnancy risk.
• Ectopic pregnancy: Implantation outside uterine cavity (commonly in fallopian tube). Presents with abdominal pain and bleeding; is a medical emergency.
• Turner syndrome (45,X): Female with streak ovaries, short stature, primary amenorrhoea and infertility.
• Klinefelter syndrome (47,XXY): Male with small testes, reduced testosterone, azoospermia or oligospermia, infertility, sometimes gynecomastia.
• Varicocele: Dilation of testicular veins, can raise scrotal temperature and reduce sperm quality.
• Cervical cancer: Often linked to human papillomavirus (HPV); preventable by screening (Pap smear) and vaccination.

Diagnosis

• History and physical exam, menstrual and sexual history.
• Hormone assays: FSH, LH, estrogen, progesterone, prolactin, testosterone, TSH.
• Imaging: pelvic ultrasound, transvaginal ultrasound, hysterosalpingography (for tubal patency), scrotal ultrasound.
• Microbiology: STI screening (chlamydia, gonorrhoea, HIV, HPV).
• Genetic testing and karyotyping for suspected chromosomal abnormalities.
• Semen analysis for male infertility.

Treatment & Management

• Medical: hormonal therapies (OCPs, clomiphene, letrozole for ovulation induction, testosterone replacement), antibiotics for infections.
• Surgical: laparoscopy for endometriosis or ectopic pregnancy, varicocelectomy, removal of fibroids or ovarian cysts, assisted reproductive techniques (IVF, ICSI) for infertility.
• Preventive: HPV vaccination, safe sex, early STI treatment, weight management and lifestyle changes for PCOS.

Impact on Fertility & Reproductive Outcomes

Many disorders reduce fertility by preventing ovulation, blocking gamete transport, damaging gonadal tissue, or interfering with implantation. Timely diagnosis and appropriate treatments (medical, surgical, or ART) can restore fertility in many cases.

When to Refer / Emergency Signs

• Suspected ectopic pregnancy (severe abdominal pain, shoulder pain, fainting).
• Heavy vaginal bleeding, high fever with pelvic pain (possible PID).
• Rapidly enlarging pelvic mass or suspicious lesions (possible malignancy).

Summary

Reproductive system disorders are diverse but often manageable if detected early. Combining clinical evaluation, laboratory tests, imaging and genetics helps determine cause and appropriate treatment — from medications and surgery to assisted reproductive technologies.

Fig 21 — Educational Diagram: Sex Determination and Differentiation

Overview

Sex determination is the genetic or environmental process that establishes whether an individual will develop as male or female. Sex differentiation is the subsequent cascade of molecular, hormonal and morphogenetic events that produce male or female reproductive anatomy and physiology.

Genetic systems of sex determination

• XY system (humans, most mammals): Presence of Y (specifically the SRY gene on Y) initiates male pathway; typical karyotypes: 46,XY = male, 46,XX = female.
• ZW system (birds, some reptiles): Females are ZW and males are ZZ; the heterogametic sex is female.
• Haplodiploidy (bees, ants): Fertilized eggs (diploid) develop into females, unfertilized (haploid) into males.
• X:A ratio (Drosophila): Sex determined by the ratio of X chromosomes to sets of autosomes (X/A). Typical rule: X/A ≈ 1 = female; X/A ≈ 0.5 = male; intermediate ratios = intersex.
• Environmental sex determination: e.g., temperature dependent sex determination in many reptiles.

Molecular trigger in humans

SRY (Sex-determining Region Y) encodes TDF (testis-determining factor). If SRY is active (usually on Y), the indifferent gonadal ridge develops into testes. Without SRY, it develops into ovaries.

Pathways of differentiation (internal and external genitalia)

• Male pathway (SRY present): Testis differentiation → Sertoli cells secrete anti-Mullerian hormone (AMH/MIS) causing regression of Mullerian ducts; Leydig cells secrete testosterone, which stabilizes Wolffian ducts that form epididymis, vas deferens and seminal vesicles. Testosterone is converted by 5-alpha reductase to dihydrotestosterone (DHT), responsible for masculinization of external genitalia (penis, scrotum).
• Female pathway (SRY absent): Ovarian development → no AMH so Mullerian ducts persist and differentiate into fallopian tubes, uterus and upper vagina; lack of high androgen/DHT results in female external genitalia.

Timing (human embryo)

Indifferent gonads arise by about 5th–6th week. SRY expression and testis differentiation begins around weeks 6–7. By weeks 8–12, internal and external genital differentiation become morphologically distinct.

Dosage compensation and X-inactivation

In mammals, females have two X chromosomes; to equalize X-linked gene expression between sexes, one X in each cell is inactivated (Lyonization) forming a Barr body. XIST RNA coats the inactive X and initiates silencing. Mosaic X-inactivation explains phenomena such as calico cat coat patterning (heterozygous for X-linked coat color).

Clinical examples and variations

• Turner syndrome (45,XO): Phenotype female with ovarian dysgenesis, short stature.
• Klinefelter syndrome (47,XXY): Phenotype male with hypogonadism, small testes, reduced fertility.
• Androgen Insensitivity Syndrome (46,XY with defective androgen receptor): Genetically male but external phenotype female; presence of testes and AMH causes absent uterus.
• Congenital adrenal hyperplasia (46,XX with excess androgens): Genetic female with virilized external genitalia.

Summary

Sex determination (genetic or environmental) sets the developmental program; sex differentiation is executed by gene regulation and hormones (SRY, AMH, testosterone, DHT) acting on embryonic ducts and tissues. Variations occur due to chromosomal anomalies, gene mutations or abnormal hormone action.

Fig 22 — Educational Diagram: Additional Concepts and Practical Skills

Overview
This section supplements the Class 12 chapter on Human Reproduction with laboratory‑oriented concepts and practical skills commonly required in reproductive biology and clinical practice: semen analysis, basic calculations used in reproduction, Assisted Reproductive Technologies (ART), prenatal diagnostic techniques and the interpretation of hormone profiles and pregnancy tests. Emphasis is on conceptual understanding, common procedures, safety, ethics and interpretation of results.

Semen analysis (basic practical skill)
Semen analysis is a routine test to evaluate male fertility. Key parameters: volume, pH, sperm concentration, total sperm count, motility (progressive and non‑progressive), viability and morphology.

• Typical reference ranges (WHO 2010/2012): volume 1.5–5.0 mL; sperm concentration ≥ 15 million/mL; total motility (progressive + non‑progressive) ≥ 40%; progressive motility ≥ 32%; normal morphology (strict) ≥ 4%.
• Basic steps: collect sample by masturbation into a sterile container after 2–7 days abstinence; allow liquefaction (usually 20–60 minutes at 37°C); measure volume and pH; prepare wet mounts for motility; dilute and count using a haemocytometer for concentration; stain for morphology/viability if required.
• Haemocytometer counting: dilute sample (common dilution 1:20), load chamber, count sperm in defined squares and apply haemocytometer formula to get concentration (sperm/mL).

Calculations and simple formulas
Useful formulae used in clinical and lab practice include sperm count calculations, expected delivery date (Naegele's rule) and haemocytometer formulas. (See “formulas” below.)

Hormonal profiles and menstrual cycle interpretation
Interpreting how FSH, LH, oestradiol and progesterone change during the menstrual cycle is a key practical skill. Typical features: a follicular rise of oestradiol, a mid‑cycle LH surge (induces ovulation), and a post‑ovulatory rise in progesterone from corpus luteum. Correlate these hormonal changes with ovarian events (follicular growth, ovulation, corpus luteum) and uterine changes (menstrual, proliferative, secretory phases).

Pregnancy testing and prenatal diagnostics
Pregnancy tests detect human chorionic gonadotropin (hCG) in urine or blood (sensitive immunoassays). Prenatal diagnostic techniques include chorionic villus sampling (CVS) at ~10–12 weeks and amniocentesis at ~15–18 weeks for genetic testing. Understand indications, timing, sample type, and major risks (e.g., small risk of miscarriage) and counselling/ethical considerations.

Assisted Reproductive Technologies (ART) — practical outline
Common ARTs: In vitro fertilisation (IVF) with embryo transfer, Intracytoplasmic sperm injection (ICSI), Gamete/zygote intrafallopian transfer (GIFT/ZIFT). Key practical steps for IVF: ovarian stimulation, oocyte retrieval, sperm preparation, in vitro fertilisation (or ICSI), embryo culture and assessment, embryo transfer and luteal support. Counselling on success rates, multiple pregnancy risks and costs is essential.

Contraception — mechanism & practical considerations
Understand major methods: barrier (condom), hormonal (combined oral contraceptives, progestin‑only), intrauterine devices (copper, levonorgestrel), emergency contraception, and sterilisation (vasectomy, tubectomy). For each know mechanism (prevent ovulation, block sperm, prevent implantation), efficacy, side effects and suitability.

Safety, ethics and counselling
Practical skills include obtaining informed consent, maintaining confidentiality, counselling patients/clients about options and outcomes, recognising cultural and ethical aspects (e.g., decisions around prenatal testing, ART, contraception) and following biosafety procedures when handling human samples.

Quick practical tips

• Always record patient history (abstinence period, medications, previous fertility tests).
• Use standardised procedures and WHO reference ranges for semen analysis.
• When interpreting hormone graphs or pregnancy tests, use time from LMP (last menstrual period) to align events.
• Counsel couples about lifestyle factors affecting fertility (smoking, alcohol, BMI, heat exposure for testes).